Own CSL (ASX:CSL) shares? Here's why the company is moving on from COVID research

Coronavirus variants are proving resilient against a range of vaccines.

| More on:
gloved hand holding covid-19 vaccine against backdrop of australian flag

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) shares are joining the broader ASX selloff today, down 3.93% to $248.20 per share.

The S&P/ASX 200 Index (ASX: XJO) is falling hard too, down 1.47% after posting early morning gains of 0.5%.

That's today's CSL share price action.

Now we turn to why CSL is throwing in the towel on its 2-year long research into COVID-19 vaccines.

Why is CSL moving on from COVID research?

CSL has long been involved in formulating novel vaccines against a range of ailments.

When the coronavirus went global in early 2020, CSL turned its sights onto beating the virus that stemmed from Wuhan, China.

In a partial success story, the biopharmaceutical company manufactured AstraZeneca under license for Australia distribution in Melbourne. Following the reports that AstraZeneca could lead to blood clots in certain rare cases, primarily among younger people, the vaccine was eventually rebranded as Vaxzevria.

However, CSL's efforts at creating its own COVID vaccine eventually failed. The trial vaccine created together with researchers at the University of Queensland had promising results. But the drug was pulled after revelations that it could lead to false positive tests for HIV.

CSL also was part of a larger group of global companies working on a hyperimmune therapy in 2020. That project was ditched after it failed to meet expectations.

Now, as The Australian reports, "CSL … has quietly pulled the plug on developing Covid-19 antiviral treatments as it steams ahead on other projects in its $1bn-a-year research program."

According to a CSL spokesman, "CSL is proud of the role we have played in bringing the Vaxzevria vaccine to millions of Australians, as well as neighbouring countries. At present we are not investigating any antiviral treatments for Covid-19."

But that doesn't spell the end of the company's $1 billion annual research program.

In December, CSL chairman Brian McNamee said (quoted by The Australian):

We are firmly committed to advancing our next-generation sa-mRNA vaccine technology which aims to address some of the challenges presented by the current technology. We will utilise our global network, including research facilities in Cambridge, Massachusetts and clinical scale manufacturing facilities in Holly Springs, North Carolina, to achieve this.

How have CSL shares been performing?

CSL shares have been on a bit of a rollercoaster over the past 12 months, leaving them down 10%. By comparison the ASX 200 is relatively flat since this time last year.

So far in 2022, CSL shares have fallen 15%.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »